Mackenzie Financial
CYCN icon

Mackenzie Financial’s Cyclerion Therapeutics CYCN Stock Holding History

Mackenzie Financial’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,475
Closed -$19.4K – 1540
2022
Q4 		$19.4K Buy
1,475
+109
+8% +$1.29K ﹤0.01% 1402
2022
Q3 		$23K Sell
1,366
-680
-33% -$11.7K ﹤0.01% 1404
2022
Q2 		$22K Buy
2,046
+781
+62% +$11.2K ﹤0.01% 1436
2022
Q1 		$28K Buy
+1,265
New +$30.5K ﹤0.01% 1386

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mackenzie Financial's CYCN Position: Q1 2023 in Review

Mackenzie Financial sold out of Cyclerion Therapeutics (CYCN) in Q1 2023, closing a stake of 1,475 shares — an estimated $19.4K sold.

Mackenzie Financial first reported a position in CYCN in Q1 2022 and held it in 4 quarters. The position peaked at $28K in Q1 2022. 34 funds tracked by Wall St. Rank hold CYCN as of Q1 2023.

  • Mackenzie Financial reported no remaining Cyclerion Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Mackenzie Financial sold 1,475 Cyclerion Therapeutics shares in Q1 2023, an estimated $19.4K.
  • Mackenzie Financial first reported a position in Cyclerion Therapeutics in Q1 2022 and held it in 4 quarters.
  • Mackenzie Financial's Cyclerion Therapeutics position peaked at $28K in Q1 2022.
  • 34 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2023.

Based on Mackenzie Financial's 13F filing for Q1 2023, filed 24 Apr 2023.